Volume 04 Issue 07-2024
23
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
07
P
AGES
:
23-28
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
Osteoarthritis (OA) is one of the most common chronic degenerative joint diseases, significantly affecting the quality
of life of patients. The COVID-19 pandemic has revealed the long-term effects of the SARS-CoV-2 virus, including the
development of OA. The object of this study is the impact of COVID-19 on the clinical, immunological, and genetic
features of OA. The article discusses the mechanisms leading to inflammatory processes in the joints, as well as genetic
aspects that may be associated with cartilage regeneration. Patients after COVID-19 have more pronounced OA
symptoms, which confirms the need for further study of this relationship to develop effective approaches to
treatment and rehabilitation.
KEYWORDS
Research Article
CLINICAL FEATURES AND IMMUNOLOGICAL MECHANISMS OF
DEVELOPMENT OF OSTEOARTHRITIS OF THE FEMORAL HIP JOINT
Submission Date:
Aug 02, 2024,
Accepted Date:
Aug 07, 2024,
Published Date:
Aug 12, 2024
Crossref doi:
https://doi.org/10.37547/ijmscr/Volume04Issue08-03
Shodikulova Gulandom Zikriyayevna
Professor, Samarkand State Medical University, Samarkand, Uzbekistan
Gulomov Jahongir Ibrokhimovich
Assistant, Samarkand State Medical University, Samarkand, Uzbekistan
Pulatov Ulugbek Sunatovich
PhD, docent, Samarkand State Medical University, Samarkand, Uzbekistan
Khasanov Oybek Gafurovich
Assistant, Samarkand State Medical University, Samarkand, Uzbekistan
Journal
Website:
https://theusajournals.
com/index.php/ijmscr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 04 Issue 07-2024
24
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
07
P
AGES
:
23-28
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Osteoarthritis (OA), COVID-19, SARS-CoV-2 virus, femoral hip joint, interleukin-6 (IL-6) and interleukin-8 (IL-8), tumor
necrosis factor-alpha (TNF-
α), non
-steroidal anti-inflammatory drugs (NSAIDs).
INTRODUCTION
Osteoarthritis (OA) is one of the most common chronic
degenerative joint pathologies, significantly affecting
patients' quality of life and ability to work. The COVID-
19 pandemic caused by the SARS-CoV-2 virus has shown
that the infection can have long-lasting effects on
various div systems. Recent studies show the impact
of COVID-19 on the clinical, immunological, and genetic
features of OA development in patients with this
infection. This literature review aims to deepen our
understanding of the pathogenesis of the disease and
to search for possible mechanisms of COVID-19's
influence on osteoarthritis.
Impact of viral infections on the immune system:
Recent studies have shown that COVID-19 can cause
various immune system disturbances, including
activation of inflammatory processes. SARS-CoV-2
causes an enhanced immune response accompanied
by increased levels of cytokines and inflammatory
markers. This inflammatory response may contribute
to the development and progression of OA in COVID-19
patients.
Clinical manifestations of OA after COVID-19:
Observations show that COVID-19 patients present
with osteoarthritis with some peculiarities compared
to normal OA. These patients have more severe pain,
limitation of mobility and joint inflammation. This may
be due to the effect of the virus on cartilage tissues as
well as surrounding structures and joints.
Genetic aspects of OA after COVID-19: There is
evidence of abnormalities in genetic mechanisms
related to cartilage regeneration and metabolic
processes in joints in patients with OA after COVID-19.
Some genes associated with cartilage formation and
destruction may play a role in the pathogenesis of OA
after infection. Genetic predisposition studies help to
identify risk groups and understand the molecular
mechanisms involved in the pathogenesis of OA after
COVID-19.
Despite the relative novelty of the problem, existing
studies point to possible clinical, immunological, and
genetic features of OA in COVID-19 patients. Continued
research in this area is important to better understand
the molecular mechanisms and to develop tailored
treatment and rehabilitation strategies to prevent or
delay the development of OA after COVID-19.
Volume 04 Issue 07-2024
25
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
07
P
AGES
:
23-28
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Risk factors and metabolic disorders: To understand
the etiopathogenesis of the disease, it is important to
consider risk factors such as age, obesity, diabetes
mellitus, hypertension, and dyslipidemia. One
mechanism explaining the association between
metabolic disorders and OA is chronic inflammation
associated with metabolic diseases. Inflammatory
cytokines such as interleukin-
1β (IL
-
1β) and tumor
necrosis factor-alpha (TNF-
α) activate destr
uctive
processes in cartilage and promote its degeneration.
Traumatic osteoarthritis: Mechanisms associated with
the development of traumatic osteoarthritis include
damage to joint structures, cartilage, and synovial
membrane, inflammation, and immune cell activation.
Traumatic injury causes inflammatory processes that
lead to the release of cytokines such as interleukin-6
(IL-6) and interleukin-8 (IL-8) that activate destructive
processes in cartilage and promote cartilage
degeneration.
Effect of drugs: Drugs play an important role in the
treatment and management of osteoarthritis.
Different classes of drugs have different effects on the
pathogenesis and symptoms of osteoarthritis. For
example, non-steroidal anti-inflammatory drugs
(NSAIDs) are widely used to relieve pain and
inflammation in OA, but their long-term use can cause
serious side effects. Glucosamine and chondroitin
sulfate may have a positive effect on cartilage tissue
and reduce OA symptoms, but their effectiveness
requires further research.
Genetic disorders: Genetic factors play an important
role in the development of osteoarthritis. Several
genes related to the metabolism of cartilage
components, collagen structure, and proteoglycans
are of potential importance in the development of the
disease. For example, polymorphisms in the COL2A1
gene encoding type II collagen may contribute to
impaired cartilage structure and increased risk of
osteoarthritis.
Genes
encoding
matrix
metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs), as well as cytokines such
as IL-
1β and TNF
-
α, may also play a role in the
pathogenesis of osteoarthritis. Alterations in these
genes may affect the activity of cartilage-related
enzymes and joint inflammation.
Thus, the etiopathogenesis of osteoarthritis is a
complex and multifaceted process involving various
risk factors, metabolic disorders, traumatic injuries,
drug effects, and genetic factors. Age, gender, obesity
and occupational factors significantly influence the
development of the disease. Metabolic disorders,
especially those associated with metabolic syndrome,
also play an important role in the pathogenesis of
osteoarthritis. Traumatic osteoarthritis may result
from joint injuries leading to inflammatory and
degenerative processes. Medications such as NSAIDs,
glucosamine and chondroitin sulfate may have a
Volume 04 Issue 07-2024
26
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
07
P
AGES
:
23-28
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
positive effect on osteoarthritis symptoms but require
further
research.
Genetic
factors,
including
polymorphisms of genes related to cartilage
metabolism and inflammation, also play an important
role in the development of osteoarthritis.
Etiopathogenesis of COVID-19 and its musculoskeletal
complications: COVID-19, caused by the SARS-CoV-2
coronavirus, has become one of the most serious
public health problems in world history. Since the start
of the pandemic in late 2019, the disease continues to
spread and affect various div systems. The main
symptoms of COVID-19 are related to the respiratory
system, but a growing div of research points to
possible complications in other systems, including the
musculoskeletal system.
Etiopathogenesis of COVID-19: The SARS-CoV-2
coronavirus enters div cells via angiotensin-
converting enzyme 2 (ACE2) receptors widely
distributed in various tissues, including lungs, heart,
kidneys, blood vessels, and musculoskeletal tissues.
Infection causes systemic inflammation and activation
of the immune system, leading to a complex set of
molecular and cellular responses.
Complications of COVID-19 in the musculoskeletal
system are:
1. Myalgia and arthralgia: One of the most common
symptoms of COVID-19 is muscle pain (myalgia) and
joint pain (arthralgia). These symptoms may be caused
by systemic exposure to the virus or the div's
response to a viral infection. Studies show that myalgia
occurs in 45% of patients with COVID-19. These
symptoms can cause significant discomfort and limit
mobility.
2. Joint inflammation: In some patients, COVID-19 may
cause joint inflammation, leading to arthritis-like
symptoms. Research suggests that the virus may cause
inflammatory processes in the joints, leading to
rheumatic symptoms. This may cause pain, swelling,
and limitation of joint motion.
3. Myopathies: COVID-19 may cause musculoskeletal
disorders such as myopathies. These disorders may be
caused by the direct effect of the virus on the muscles
or by inflammatory processes caused by the div’s
immune response. Patients may experience muscle
weakness, pain, and limitation of motion.
4. Thrombosis and embolism: COVID-19 is associated
with an increased risk of thrombotic complications
such as vascular thrombosis and pulmonary embolism.
These complications may be due to hypercoagulability,
inflammatory changes, and damage to the vascular
wall.
CONCLUSION
Thus, studies show that osteoarthritis (OA) may be
exacerbated in patients after COVID-19 due to immune
system disorders, clinical manifestations, and genetic
Volume 04 Issue 07-2024
27
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
07
P
AGES
:
23-28
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
factors. The SARS-CoV-2 virus activates inflammatory
processes, which may accelerate the development of
OA. In this case, specific clinical symptoms are
observed, such as increased pain and limited joint
mobility. Genetic mechanisms associated with
cartilage regeneration may also play an important role
in the pathogenesis of OA in patients after COVID-19. It
is important to consider risk factors such as age,
comorbid diseases, and metabolic disorders, which can
aggravate the course of the disease. This emphasizes
the need for further research to develop specific
therapeutic strategies and rehabilitation measures.
REFERENCES
1.
Coaccioli S. et al. Osteoarthritis: New insight on its
pathophysiology //Journal of Clinical Medicine.
–
2022.
–
Т. 11. –
№. 20. –
С. 6013.
2.
Chow YY, Chin KY. The Role of Inflammation in the
Pathogenesis
of
Osteoarthritis.
Mediators
Inflamm.
2020
Mar
3;2020:8293921.
doi:
10.1155/2020/8293921. PMID: 32189997; PMCID:
PMC7072120.
3.
Endstrasser F, Braito M, Linser M, Spicher A,
Wagner M, Brunner A. The negative impact of the
COVID-19 lockdown on pain and physical function
in patients with end-stage hip or knee
osteoarthritis. Knee Surg Sports Traumatol
Arthrosc.
2020
Aug;28(8):2435-2443.
doi:
10.1007/s00167-020-06104-3. Epub 2020 Jun 18.
PMID: 32556438; PMCID: PMC7299668.
4.
Katz J. N., Arant K. R., Loeser R. F. Diagnosis and
treatment of hip and knee osteoarthritis: a review
//Jama.
–
2021.
–
Т. 325. –
№. 6. –
С. 568
-578.
5.
Khella C. M. et al. An evidence-based systematic
review
of
human
knee
post-traumatic
osteoarthritis
(PTOA):
timeline
of
clinical
presentation and disease markers, comparison of
knee joint PTOA models and early disease
implications //International Journal of Molecular
Sciences.
–
2021.
–
Т. 22. –
№. 4. –
С. 1996.
6.
Kijima H. et al. The differences in imaging findings
between painless and painful osteoarthritis of the
hip //Clinical Medicine Insights: Arthritis and
Musculoskeletal Disorders.
–
2020.
–
Т. 13. –
С.
1179544120946747.
7.
Motta F. et al. Inflammaging and osteoarthritis
//Clinical Reviews in Allergy & Immunology.
–
2023.
–
Т. 64. –
№. 2. –
С. 222
-238.
8.
Molnar V. et al. Mesenchymal stem cell
mechanisms of action and clinical effects in
osteoarthritis: a narrative review //Genes.
–
2022.
–
Т. 13. –
№. 6. –
С. 949.
9.
Shodikulova G. Z. et al. The Correlation among
Osteoporosis, Calcium-Phosphore Metabolism and
Clinical Symptoms of Main Disease in Patients with
Rheumatoid Arthritis //Annals of the Romanian
Society for Cell Biology.
–
2021.
–
С. 4185
-4190.
10.
Trivanovic D. et al. Immune and stem cell
compartments of acetabular and femoral bone
marrow
in
hip
osteoarthritis
patients
Volume 04 Issue 07-2024
28
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
04
ISSUE
07
P
AGES
:
23-28
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
//Osteoarthritis and Cartilage.
–
2022.
–
Т. 30. –
№.
8.
–
С. 1
116-1129.
11.
Zikriyayevna S. G. et al. HEART RHYTHM
DISTURBANCES
IN
CONNECTIVE
TISSUE
DYSPLASIA //International Journal of Medical
Sciences And Clinical Research.
–
2024.
–
Т. 4. –
№.
06.
–
С. 32
-39.
12.
Zikriyayevna S. G. et al. FUNCTIONAL COMPONENT
OF
THE
CARDIOVASCULAR
SYSTEM
IN
INDIVIDUALS
WITH
CONNECTIVE
TISSUE
DYSPLASIA //International Journal of Medical
Sciences And Clinical Research.
–
2024.
–
Т. 4. –
№.
06.
–
С. 24
-31.
13.
Киямова Л. и др. СОВРЕМЕННЫЕ АСПЕКТЫ
ЛЕЧЕНИЯ
СИНДРОМА
ГИПЕРАКТИВНОГО
МОЧЕВОГО ПУЗЫРЯ //Models and methods in
modern science.
–
2024.
–
Т. 3. –
№. 1. –
С. 237
-243.
14.
Киямова Л. и др. ДИАГНОСТИКА СИНДРОМА
ГИПЕРАКТИВНОГО
МОЧЕВОГО
ПУЗЫРЯ
//Theoretical aspects in the formation of
pedagogical sciences.
–
2024.
–
Т. 3. –
№. 2. –
С. 138
-
145.
15.
Киямова Л. и др. ОСОБЕННОСТИ ТЕЧЕНИЯ
ОСЛОЖНЕННОГО
ГЕСТАЦИОННОГО
ПИЕЛОНЕФРИТА У БЕРЕМЕННЫХ //Solution of
social problems in management and economy.
–
2024.
–
Т. 3. –
№. 1. –
С. 194
-201.
16.
Пулатов У. С., Суюнов А. Ф. ПОЛИМОРФИЗМ
ГАПТОГЛОБИНА
У
БОЛЬНЫХ
С
РЕВМАТОИДНЫМ АРТИРОМ //" Conference on
Universal Science Research 2023".
–
2023.
–
Т. 1. –
№. 2. –
С. 120
-123.
17.
Пулатов У., Нематуллаев Ж., Шопулотова З.
ОСТРЫЕ
РЕСПИРАТОРНЫЕ
ВИРУСНЫЕ
ИНФЕКЦИИ:
СИМПТОМЫ,
ЛЕЧЕНИЕ
И
ПРОФИЛАКТИКА
//Евразийский
журнал
медицинских и естественных наук. –
2024.
–
Т. 4.
–
№. 5. –
С. 269
-273.
18.
Пулатов У. С. и др. ОСОБЕННОСТИ ЛЕЧЕНИЯ ПРИ
ХПН
//INNOVATIVE
DEVELOPMENTS
AND
RESEARCH IN EDUCATION.
–
2023.
–
Т. 2. –
№.
23.
–
С. 303
-305.
19.
Шодикулова Г. З. и др. СОВРЕМЕННЫЙ ВЗГЛЯД
НА ПРОБЛЕМУ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ У
БОЛЬНЫХ С ПОДАГРОЙ И БЕССИМПТОМНОЙ
ГИПЕРУРИКЕМИЕЙ //Journal of cardiorespiratory
research.
–
2023.
–
Т. 1. –
№. 1. –
С. 28
-33.
20.
Шодикулова Г. З., Мирзаев О. В., Саматов Д. К.
РАСПРОСТРАНЕННОСТЬ
И
КЛИНИКО
-
ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ ДИСПЛАЗИИ
СОЕДИНИТЕЛЬНОЙ ТКАНИ У ЛИЦ УЗБЕКСКОЙ
ПОПУЛЯЦИИ
//Journal
of
cardiorespiratory
research.
–
2023.
–
Т. 1. –
№. 1. –
С. 94
-98.
